Page 3 - Sci Communications News Today

RALEIGH, NC / ACCESSWIRE / September 6, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced

Press release content from Accesswire. The AP news staff was not involved in its creation.

Employees and consumers alike expect companies to take meaningful steps toward creating a more equitable and inclusive future.

RALEIGH, NC / ACCESSWIRE / July 6, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced

/PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a...

9 Meters Biopharma Announces Debt Facility to Support Phase 3 Study of Vurolenatide for Short Bowel Syndrome - Initial Draw of $20 Million to Support Funding Phase 3 Development... | June 30, 2022

• The primary outcome of the MGT009 study is safety, and botaretigene sparoparvovec treatment was found to be generally safe and well-tolerated • Significant improvements were... | June 28, 2022

Additional analyses to determine if a subgroup of patients and/or symptoms may have been responsive to treatmentCompany remains on track to deliver vurolenatide Phase 2 short bowel syndrome results by

9 Meters Biopharma Announces Interim Analysis of Phase 3 Study of Larazotide for Celiac Disease Does Not Support Trial Continuation -Additional analyses to... | June 21, 2022

13.06.2022 - RALEIGH, NC / ACCESSWIRE / June 13, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced the Companys participation in the 2022 BIO ...